Document is current
Any future updates will be listed below
-
Authors
Valensi, Paul
Esser, Rémi
Picard, François
Jagu, Annabelle
Tartière, Jean-Michel
Maillard, Gwénael
Pages, Nicolas
Nisse-Durgeat, Sophie
Hanon, Olivier
- License Information
-
More Information
Article History
Received: 11 May 2026
Accepted: 10 August 2026
First Online: 25 August 2026
Declarations
Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki and complied with French national regulations and the General Data Protection Regulation (GDPR). The telemonitoring program was approved by the appropriate national regulatory authorities. All participants provided informed consent at the time of enrollment in the Satelia ® Cardio program. As this was a retrospective analysis of anonymized routinely collected data, no additional ethical approval was required.
Consent for publication: Not applicable.
Competing interests: PV discloses the following potential conflicts of interest: lectures for Abbott, AstraZeneca, Bayer, Clinica Medica, Eli Lilly, Hikma Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Novartis, Philadelphia, Pfizer, Sanofi, Servier, Stendo; research grants from Abbott, Bristol-Myers Squibb–AstraZeneca, Novo Nordisk; participation in expert committees for AstraZeneca, Boehringer Ingelheim, CEMKA, Novo Nordisk, Daiichi Sankyo, Sanofi, Servier. NP is the founder and shareholder of NP Medical. SN-D and NP are employed by NP Medical. All other authors declare no conflicts of interest.
